Mettler-Toledo International Inc. (MTD) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. While there is growth in China and emerging markets, and positive pipeline activity, macro uncertainties and chemical softness in Europe pose challenges. The cautious but optimistic outlook, combined with modest financial guidance and a strong service business, suggests a neutral sentiment overall. Share repurchases and free cash flow growth are positive, but the lack of significant improvement in market conditions tempers expectations. Without a market cap, it's unclear how strongly the stock might react, but the overall sentiment leans towards a neutral impact on stock price.
Key Financial Performance
Sales $947 million, representing a 3% increase in local currency or 1% excluding acquisitions. Acquisitions contributed approximately 1.5% to growth. On a U.S. dollar reported basis, sales increased 7%.
Sales Growth by Region Local currency sales increased 2% in the Americas, 1% in Europe, and 5% in Asia/Rest of World, including 4% growth in China. Excluding acquisitions, local currency sales were flat in the Americas and increased 3% in Asia/Rest of World.
Sales Growth by Product Area Local currency sales increased 1% in Laboratory, 5% in Industrial (including 1% growth in core industrial and 11% growth in product inspection), and 7% in Food Retail. Excluding acquisitions and currency, Laboratory sales were flat, Industrial increased 2% (core industrial flat, product inspection up 6%), and service revenue grew 7% (5% excluding acquisitions).
Gross Margin 58.7%, a decrease of 80 basis points. Excluding unfavorable foreign currency and acquisitions, gross margin was up 10 basis points. Favorable price realization and supply chain optimization benefits offset an incremental gross tariff headwind of 90 basis points.
R&D Expenses $51 million, up 1% on a local currency basis over the prior period.
SG&A Expenses $258 million, a 1% increase in local currency over the prior year, including sales and marketing investments offset by cost savings.
Adjusted Operating Profit $246 million, up 4% versus the prior year. Adjusted operating margin was 26%, a decrease of 80 basis points versus the prior year or up 40 basis points excluding unfavorable currency. Incremental tariffs reduced operating profit by 4% and were a 90 basis point headwind to operating margin.
Adjusted EPS $8.91, a 9% increase over the prior year. Incremental tariff costs were a gross headwind to EPS of 4%. Reported EPS was $8.33 compared to $7.81 in the prior year.
Adjusted Free Cash Flow $120 million, negatively impacted by the timing of tax payments, which were $58 million higher than the prior year.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
EasyMax Advanced Automated Lab Reactor: Automates scale-up experiments with precise measurements, smart digital sensors, and embedded vision system for continuous data capture.
InMotion PX One Autosampler: Automates density, refractive index, and UV/VIS measurements, reducing variability and increasing repeatability while minimizing contact with toxic substances.
Low Retention Pipettes: First to market with pipettes that minimize retention of viscous liquids without using PFAS, reducing environmental impact.
Dual Energy X-ray Solutions: Utilizes advanced photon counting technology for precise contamination identification in food and pharmaceuticals.
M50 R-Series Metal Detectors: Delivers a 20% increase in detection sensitivity, engineered for modern production environments.
Geographic Expansion: Good growth in India, Southeast Asia, and emerging markets; 4% growth in China led by Industrial business.
Segment Focus: Targeting high-growth segments like biopharma, semiconductor, and new energy for future growth.
Margin Expansion: Strong execution of margin initiatives supported adjusted EPS growth despite macroeconomic uncertainties.
Innovation Investments: Continued focus on automation, digitalization, and onshoring to meet customer needs and drive growth.
Market Leadership in Product Inspection: Expanded portfolio with X-ray and metal detection solutions, achieving strong sales growth and market share gains.
Focus on Replacement Cycles and Near-shoring: Positioned to capitalize on customer replacement cycles and near-shoring activities for medium-term growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Macroeconomic Uncertainty: The company acknowledges increased uncertainty in the macroeconomic environment, which could impact customer purchasing patterns and overall market conditions.
Geopolitical Risks: The ongoing conflict in the Middle East has led to higher global energy costs and increased uncertainty in end markets, causing customer delays and potential cost pressures.
Tariff Costs: Incremental tariffs have created a 90 basis point headwind to gross margin and a 4% reduction in operating profit, with further uncertainties around future tariff rates and potential refunds.
Inflationary Pressures: Higher costs due to inflation, partly driven by geopolitical tensions, are expected to impact operations, though the company is attempting to mitigate these through cost savings and pricing actions.
Soft Demand in Specific Segments: Declines in pipette sales due to soft demand from academia and biotech customers, as well as cautious purchasing patterns in core industrial markets, are affecting growth.
Supply Chain Challenges: While supply chain optimization has provided some benefits, the company continues to face challenges, including gross tariff headwinds and potential disruptions.
Customer Delays: Customer delays in the Americas and other regions, attributed to increased market uncertainty, are impacting sales growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year 2026 Local Currency Sales Growth: Forecast remains at approximately 4%, including a contribution from acquisitions, which will approximate 1.5% in the first half of the year and less than 8% for the full year.
Full Year 2026 Adjusted EPS: Forecasted to be in the range of $46.30 to $46.95, representing a growth rate of 8% to 10%. This reflects an increase from the previous guidance of 8% to 9% growth.
Second Quarter 2026 Local Currency Sales Growth: Expected to grow approximately 3%, including a benefit of approximately 1.5% from acquisitions.
Second Quarter 2026 Adjusted EPS: Expected to be in the range of $10.70 to $10.85, a growth rate of 6% to 8%.
Foreign Exchange Impact: Estimated to be a 2% benefit to sales growth and neutral to EPS for the full year 2026.
Free Cash Flow for 2026: Expected to be approximately $900 million, an increase of 5% on a per share basis.
Share Repurchases for 2026: Expected to be in the range of $825 million to $875 million.
Tax Rate for 2026: Expected to remain at 19% before discrete items.
Growth in Biopharma and Emerging Markets: Anticipated gradual increase in activity in the second half of the year, with strong growth expected in biopharma, new energy, and semiconductor segments.
Customer Replacement Cycles and Near-shoring Activities: Expected to drive growth opportunities over the coming years.
Margin Expansion Targets: Ample opportunity to deliver strong margin expansion this year and beyond, despite increased uncertainty related to the conflict in the Middle East.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchases: Share repurchases are expected to be in the range of $825 million to $875 million for the year 2026.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the updated guidance for full-year LC sales growth and M&A contribution?
A:The company reiterated a 4% LC sales growth for the full year. The M&A contribution was updated to 1.5% for the first half and slightly less than 1% for the full year, compared to the previous guidance of 1% for the first half and 0.5% for the year.
Q:What is the outlook for the organic business and specific segments like Lab and Industrial?
A:The organic business shows a modest reduction due to macro uncertainties. For the full year, Lab is expected to grow at low to mid-single digits, with Q2 organic growth at low single digits. Core Industrial is projected at low to mid-single digits for the year, with low single digits organically. Product Inspection is expected to grow mid-single digits for the year, with Q2 organic growth at low single digits.
Q:What are the dynamics in the Americas and Europe for Q2 and the full year?
A:In the Americas, full-year growth is expected at low single digits, with Q2 being flattish due to lumpiness in the retail business. In Europe, full-year growth is projected at low single digits, with Q2 at low to mid-single digits, reflecting improvements in bioprocessing.
Q:What is driving growth in China, and what are the expectations for the full year?
A:China has shown strong momentum, particularly in the Industrial business and pharma sectors. Full-year growth expectations for China have been increased to mid-single digits, driven by investments in automation and pharma-related activities.
Q:What is the outlook for the retail business in the Americas?
A:The retail business is described as lumpy, with Q1 showing a double-digit decline in the U.S. but strong growth in Europe. Overall, retail grew high single digits in Q1. The outlook remains positive due to new innovations and strong market reception.
Q:What is the impact of the middle market strategy in China on the PID business?
A:The strength in China is attributed to core automation and industrial business rather than the PID business. Investments in automation and pharma are driving growth, with opportunities in QA/QC and R&D labs.
Q:What is the pipeline activity and growth outlook for the second half of the year?
A:Pipeline activity shows positive indicators, with growth expected to improve in the second half. The company is cautious but optimistic, citing no cancellations and a strong funnel of opportunities.
Q:What is causing chemical softness in Europe, and what is the outlook?
A:Chemical softness in Europe is attributed to high energy costs, leading to cautious investments. The outlook remains uncertain, with some impact on process analytics and lab businesses.
Q:How is cost management being handled in the current environment?
A:The company is focused on mitigating costs related to fuel, transportation, and input materials. Benefits from tariff changes are expected to offset some headwinds, with potential upside from mitigation actions.
Q:What is the breakdown of price versus volume in the guidance?
A:Price contributed 3.5% in Q1 and is expected to be around 2.5% in Q2, with a normalized 2% for the second half. Full-year price contribution is projected at 2.5%, with potential upside.
Q:What is the outlook for the core industrial business in Western markets?
A:Core Industrial in Western markets shows some softness due to macro uncertainties. However, automation and digitalization trends are driving growth, with optimism for future opportunities in reshoring and replacement cycles.
Q:What is the service business growth and attach rate?
A:Service business grew 7% in Q1, with 5% organic growth. The company is focused on increasing attach rates and covering more of the installed base, with strong customer loyalty and NPS scores.
Q:What is the exposure to the semiconductor industry and its performance?
A:The semiconductor-related ultra-pure water business contributes low single digits to revenue and is performing well, driven by build-outs in semiconductor and data center industries.
Q:What is the performance of bioprocessing and its competitive position?
A:Bioprocessing showed strong growth, driven by demand for automation and digital sensors. The company is well-positioned with innovative products and strong market connections.
Q:What is the impact of customer delays and chemical softness on the business?
A:Customer delays were noted in Western markets, but the pipeline suggests recovery in the second half. Chemical softness is linked to high energy costs, with some improvement expected in the second half.
Q:What is the impact of tariff changes on the business?
A:Tariff changes provided a temporary benefit in Q1, but rates are expected to normalize midyear. Inflationary pressures are being mitigated, with potential upside from cost management actions.
Q:Review of Unclear Management Responses
A:Management avoided providing specific quantifications for customer delays and chemical softness, citing general themes and uncertainties. Additionally, they did not elaborate on the exact impact of geopolitical factors or provide detailed breakdowns of pipeline activity and backlog conversion.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Americas Asia
Asia World
China acquisition
East increase
East war
IEEPA rate
Industrial product
Items share
Laboratory Industrial
Middle East
Relations statement
World Slide
achievement today
acquisition PL
acquisition currency
acquisition price
acquisition rate
action approach
activity benefit
agility margin
amortization headwind
approach nature
area currency
basis Share
benefit change
benefit investment
benefit tariff
change import
change interest
contribution acquisition
cost good
cost saving
currency acquisition
point basis
point currency
rate tariff
spot rate
tariff refund
MTD Transcript
Mettler-Toledo International Inc. (MTD) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Mettler-Toledo International Inc. (MTD) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call presents a mixed outlook. While there is growth in China and emerging markets, and positive pipeline activity, macro uncertainties and chemical softness in Europe pose challenges. The cautious but optimistic outlook, combined with modest financial guidance and a strong service business, suggests a neutral sentiment overall. Share repurchases and free cash flow growth are positive, but the lack of significant improvement in market conditions tempers expectations. Without a market cap, it's unclear how strongly the stock might react, but the overall sentiment leans towards a neutral impact on stock price.
Mettler-Toledo International Inc. (MTD) Q4 2025 Earnings Call Transcript
Unknown2-6
The earnings call presents a mixed outlook. Positive factors include growth in sales across several segments, strong performance in Europe, and optimistic guidance for 2026. However, cautious Q1 guidance, market uncertainties, and challenges in specific sectors like industrial and chemical temper expectations. Additionally, management's vague responses in the Q&A section and the expected decrease in operating margin due to higher tariff costs further contribute to a neutral sentiment. Overall, the balance of positive and negative factors suggests a neutral stock price movement in the short term.
Mettler-Toledo International Inc. (MTD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
MTD Slides
MTD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
